Evidence map›Paper›PMID 37510253›Full record

ArticleGenes2023

In Vitro Analysis of the Effect of SARS-CoV-2 Non-VOC and four Variants of Concern on MHC-Class-I Expression on Calu-3 and Caco-2 Cells.

Nora A Bahlmann, Lena Mautner, Mona Hoyos, Erwan Sallard, Carola Berger, Alexandra Dangel, Franziska Jönsson, Johannes C Fischer, Florian Kreppel, Wenli Zhang and 4 more

Abstract read
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nora A BahlmannVirology and Microbiology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.
Lena MautnerBavarian Health and Food Safety Authority, 85764 Oberschleißheim, Germany.
Mona HoyosBavarian Health and Food Safety Authority, 85764 Oberschleißheim, Germany.ORCID 0000-0003-1085-4723
Erwan SallardVirology and Microbiology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.ORCID 0000-0002-2324-3633
Carola BergerBavarian Health and Food Safety Authority, 85764 Oberschleißheim, Germany.
Alexandra DangelBavarian Health and Food Safety Authority, 85764 Oberschleißheim, Germany.ORCID 0000-0001-6737-5681
Franziska JönssonBiochemistry and Molecular Medicine, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.ORCID 0000-0001-7671-653X
Johannes C FischerInstitute for Transplant Diagnostics and Cell Therapeutics, Heinrich-Heine-University, 40204 Duesseldorf, Germany.ORCID 0000-0002-2079-1845
Florian KreppelBiochemistry and Molecular Medicine, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.
Wenli ZhangVirology and Microbiology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.ORCID 0000-0002-6243-6286
Irene EspositoInstitute of Pathology, Heinrich Heine University and University Hospital, 40204 Duesseldorf, Germany.ORCID 0000-0002-0554-2402
Edwin BölkeDepartment of Radiation Oncology, Heinrich-Heine-University, 40204 Duesseldorf, Germany.ORCID 0000-0001-9112-1024
Armin BaikerBavarian Health and Food Safety Authority, 85764 Oberschleißheim, Germany.
Anja EhrhardtVirology and Microbiology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, 58453 Witten, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the MHC-I-pathway is key to antigen presentation to cytotoxic T-cells and, therefore, recognition by the host adaptive immune system, we hypothesized that SARS-CoV-2 including its Variants of Concern (VOCs), influences MHC-I expression on epithelial cell surfaces as an immune evasion strategy. We conducted an in vitro time course experiment with the human airway epithelial cell line Calu-3 and the human colorectal adenocarcinoma cell line Caco-2. Cells were infected with SARS-CoV-2 strains non-VOC/B.1.1, Alpha/B.1.1.7, Beta/B.1.351, Gamma/P.1, and Delta/B.1.617.2. At 2, 24, 48 and 72 h post-infection we performed RT-qPCR to track viral replication. Simultaneously, we performed intracellular staining with a serum of a double-vaccinated healthy adult containing a high amount of spike protein antibody. In flow cytometry experiments, we differentiated between infected (spike protein positive) and bystander (spike protein negative) cells. To compare their HLA expression levels, cells were stained extracellularly with anti-HLA-A-IgG and anti-HLA-B,C-IgG. While HLA-A expression was stable on infected Calu-3 cells for all variants, it increased to different degrees on bystander cells in samples infected with VOCs Beta, Gamma, Delta, or non-VOC over the time course analyzed. In contrast, HLA-A levels were stable in bystander Calu-3 cells in samples infected with the Alpha variant. The upregulation of MHC-I on spike protein negative bystander cells in Calu-3 cell cultures infected with Beta, Gamma, Delta, and partly non-VOC might suggest that infected cells are still capable of secreting inflammatory cytokines like type-I interferons stimulating the MHC-I expression on bystander cells. In comparison, there was no distinct effect on HLA expression level on Caco-2 cells of any of the VOCs or non-VOC. Further investigations of the full range of immune evasion strategies of SARS-CoV-2 variants are warranted.

Indexed as

COVID-19SARS-CoV-2AdultCaco-2 CellsHumansImmunoglobulin GSpike Glycoprotein, CoronavirusImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2HLAMHC-ISARS-CoV-2 variantsVariants of Concern

Identifiers

PMID37510253
PMCPMC10378856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.